ULUSLARARASI DERGİLERDE YAYINLAR
16. I. Bavunoğlu, S. Şahin, M. Yılmaz, T. Topbaş, F. Tabak, A. Tunçkale. Native triple-valve endocarditis caused by penicilin-resistant streptococcus sanguis. Nat Clin Pract Cardiovasc Med. 2007;4:340-3.
17. Zamorano J, Erdine S, Lopez AP, Kim JH, Al Khadra A, Westergaard M, Sutradhar S, Yunis C, CRUCIAL Investigators, Collaborators (139). Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010;122:7-15.
ULUSAL YAYINLAR
1. A. Tunçkale, M. Tuncer, K. Bal, S. Hülagu, E. Sander, A. Dobrucalı, İ. Yurdakul, M. İşcan, İ. Dinç. Budd-Chiary syndrome in a man with high titer of anticardiolipin antibodies. Endoskopi 1993;4:35-39
2. A. Tunçkale, M. Güven, H. İlkova, G. Sultuypek, U. Görpe, N. Bağrıaçık. Siklosporin A’nın eritrositlerde glukoz transportu üzerine etkisi. Klinik Gelişim 1994;7:2960-296
3. A. Tunçkale, U. Görpe, M. Özyazar, M. Ayaz, R. Ataman, H. İlkova, U. Ülkü, N. Bağrıaçık. İnsülin sekresyonu ve glukoz metabolizması üzerine siklosporinin etkileri. Türk Diyabet Yıllığı 1994-1995;10:58-63
4. T. Soysal, B. Ferhanoğlu, A. Tunçkale, Y. A. Avanoğlu, N. Akman. Trombotik trombositopenik purpura olgularımız. Cerrahpaşa Tıp Fakültesi Dergisi 1994;25:233-241
5. Y. Karter, M. Tuncer, A. Tunçkale, A. Algarati, A. Yaldıran, İ. Yurdakul, F. Sipahioğlu, E. Öztürk. Helikobakter pilori eradikasyonunda yüksek doz omeprazol ve amoksisilin kombinasyonunun etkileri. Türkiye Klinikleri Gastroenterohepatoloji 1996;7:18-21
10. A. Tunçkale, E. Erginöz, Y. Karter, A. Tamer, S. Vehid, A. Yaldıran, F. Sipahioğlu, E. Öztürk. Cerrahpaşa Tıp Fakültesi genel dahiliye polikliniğinin 1995 yılı çalışmalarının değerlendirilmesi. Cerrahpaşa Tıp Dergisi 1997;28:159-62
17. A. Tunçkale. Statinlerin kolesterol düzeyini düşürmelerinin ötesindeki (pleiotropik) etkileri. Endokrinolojide Yönelişler 2003;12(1):28-31
19. A. Tunçkale. Esansiyel hipertansiyonun endokrinolojik yönleri. Türkiye Klinikleri J Int Med Sci 2006;2(20):41-4
20. H. Yanardağ, S.N. Aran, A. Tunçkale, V. Yumuk, H. Yıldız, S. Uygun, S. Demirci, T. Karayel. Serum high-density lipoprotein cholesterol: Can it be a marker of disese activity in Turkish patients with sarcoidosis? Cerrahpaşa Medical Review 2007;5:13-7.
21. S. N. Aran, A. Tunçkale, A. Belce, K. Gümüştaş, G. Aktuğlu. Total antioxidant status is not changed in atherosclerotic patients. Hipokrat Kardiyoloji 2008;42:11-5.
22. A. Tunçkale. Lipid bozukluklarına güncel yaklaşım. Hipokrat Kardiyoloji 2008;42:32-43.
23. I. Bavunoğlu, A. Tunçkale, G. Benbir, C. Akgöl, A. Çurgunlu. Klaritromisine bağlı bir deliryum olgusu. Akad Geriatri 2009;1:113-5.
ULUSLARARASI BİLDİRİLER
1. H. İlkova, U. Görpe, P. Kadıoğlu, A. Tunçkale, M. Özyazar, Ü. Korugan, N. Bağrıaçık. Nonspesific immunintervention in Type 1 diabetes of recent onset: A need for spesific approaches? 11th International Immunology and Diabetes Workshop. The 3rd International Diabetes Immunotherapy Group Symposium. 14-17 November, Nagasaki, Japan, 1991. Diabetes Research and Clinical Practice 1991;14(Suppl 1):53
2. A. Tunçkale, H. İlkova, U. Görpe, M. Özyazar, M. Ayaz, R. Ataman, N. Bağrıaçık* Effects of cyclosporine on insulin secretion and glucose metabolism. 28th Annual Meeting of the European Association for the Study of Diabetes, 8-11 September, Prague, Czechoslovakia,1992;35(Suppl 1):A39
3. H. İlkova, U. Görpe, A. Tunçkale, V. Yumuk, Z. Ersanlı, M. Özyazar, N. Bağrıaçık. İstanbul Immunotherapy Group. Clinical trials with nicotinamide: Nicotinamide biological actions and therapeutical potential in diabetes prevention. A workshop of the International Diabetes Immunotherapy Group (IDIG), 4-5 December, Copenhagen, 1992;Abstract Book:5
4. A. Tunçkale, T. Soysal, B. Ülkü, G. Aktuğlu. A randomised trial comparing the combination of ceftizoxime/netilmicin versus ceftizoxime/pefloxacin in febrile granulocytopenic patients. Journal of Drug Development 1993;6:5-7
5. Y. Karter, S. Köksal, A Tunçkale, P.Akın. The multivariate analysis (Cox regression) of the factors accepted to affect the prognosis in liver cirrhosis. Uluslar arası Gastroenteroloji Kongresi, 4-7 Haziran, İstanbul, Türkiye, 1997. Endoskopi 1997;8:89
6. R. Özaras, V. Tahan, S. Aydın, H. Uzun, G. Öztekin, A. Tunçkale, S. Dondurmacı. A nonsulfydryl ACE inhibitor, fosinopril, attenuates oxidative stress in essential hypertension. 5th Annual Meeting of the Oxygen Society, 19-23 November, Washington, USA, 1998. Free Radical Biology & Medicine 1998;25(Suppl 1):S95
7. A. Tunçkale, S. N. Aran, H. Parlar, Y. Karter, A. Yaldıran, F. Sipahioğlu, E. Öztürk. The effective dose of pravastatin to treat hypercholesterolemia in Turkish patients. 2nd Congress of the European Federation of Internal Medicine 1999;10(Suppl 1):S176
8. A. Tunçkale, I. Bavunoğlu, S. N. Aran, R. Özaras, Y. Karter, A. Yaldıran, F. Sipahioğlu, E. Öztürk. Erythropoietin as a new indicator of tubulointerstitial damage in patients with hypertensive nephropathy. 2nd Congress of the European Federation of Internal Medicine, 12-15 May, Florence, 1999. European Journal of Internal Medicine 1999;10(Suppl 1):S177
9. E. Tekgündüz, A. Çurgunlu, A. Tunçkale, Y. Karter, A. Yaldıran, E. Öztürk. Myelofibrosis caused by vitamin D deficiency in a patient with Basedow-Graves and hypomagnesaemia. 3rd Congress of the European Federation of Internal Medicine, 9-12 May, Edinburgh, 2001. European Journal of Internal Medicine 2001;12:P389
10. S. B. Altınışık, A. Çurgunlu, S. N Aran, I. B. Tüfekçi, Y. Karter, N. Ertürk, A. Tunçkale, A. Yaldıran, E. Öztürk. How common is white coat hypertension in internal medical practice? Turkish-Italian-Spanish joint meeting on hypertension & atherosclerosis, 11-16 June, Antalya, 2002;Abstract Book:OP-2
11. S. B. Altınışık, H. Karpuz, A. Tunçkale. End-organ damage in white coat hypertension. Turkish-Italian-Spanish joint meeting on hypertension & atherosclerosis, 11-16 June, Antalya, 2002;Abstract Book:OP-3
12. H. Yanardağ, S. İpekçi, Y. Güneş, A. Tunçkale, S. Demirci, T. Karayel. Systemic sarcoidosis with right orbital involvement, bilateral parotid enlargement, carpal tunnel syndrome and peripheral blood eosinophilia. 17th Asia Pacific Congress on Diseases of the Chest, 29 August-1 September, İstanbul, 2003;Chest:P325
13. A. Tunçkale, H. Yanardağ, H. Yıldız, T. Yanardağ, S. Demirci. Decreased levels of high-density lipoprotein cholesterol in patients with sarcoidosis and relationship with disease activity. 14th European Respiratory Society Annual Congress, 4-8 September, Glasgow, 2004;European Respiratory Journal:P391
14. A. Tunçkale, M. Paksoy, A. Çurgunlu, A. Karataş, E. Kara, H. Uzun, S. Aydın, S. Erdamar. Beneficial effects of tacrolimus and 5-ASA combination in rat experimental colitis. 140th Falk Symposium, Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice, 7-8 May, Dubrovnik, 2004; Abstract Book:6
15. S. Aran, A. Tunçkale, S. Tavşanoğlu, A. Dirican. Serum HDL-C levels of Turkish patients with glucose abnormalities. 75th EAS Congress, 23-26 April, Prague, 2005, Atherosclerosis 2005;6(Suppl 1):26-7
16. A. Tunçkale, S. Aran, S. Tavşanoğlu, A. Dirican. Are serum HDL-C levels of Turkish people really low? 75th EAS Congress, 23-26 April, Prague, 2005, Atherosclerosis 2005;6(Suppl 1):28
17. MS Bugdacı, S. Aran, A. Tunçkale. The presence of white coat effect in resistant hypertension does not increase end-organ damage. J Clin Hypert 2006;8 (Supplement):A41.
18. G. S. Güven, B. Ökçesiz, M. Güven, N. Bilge, M. R. Altıparmak, A. Tunçkale, S. Trablus, E. Yosunkaya, E. Karaca, S. B. Yılmaz, M. Seven, A. Yüksel. Genotoxicity evaluation in chronic renal patients undergoing hemodialysis and peritoneal dialysis, using the micronucleus test. European Human Genetics Conference 2009, May 23-26, Vienna. European Journal of Human Genetics 2009;17(Suppl 2): P03.042..
19. M. Güven, B. Batar, G. S. Güven, M. R. Altıparmak, A. Tunçkale, S. Trablus, M. Seven, E. Yosunkaya, A. Yüksel. DNA repair gene polymorphisms in dialysis patients. European Human Genetics Conference 2009, May 23-26, Vienna. European Journal of Human Genetics 2009;17(Suppl 2): P10.18.
ULUSAL BİLDİRİLER
10. Bayraktar, B. Batar, M. Güven, M.R. Altıparmak, A. Tunçkale, S. Trabulus. GSTM1 ve GSTT1 gen polimorfizmleri böbrek hastalığı için bir risk faktörü müdür? X. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, 6-9 Eylül 2007, Antalya, Özet Kitabı 218
11. M. Kanat, E. Serin, A. Tunçkale, Ö. Yıldız, S. Şahin, M. Bolayırlı, H. Arınç, A. Dirican, Y. Karagöz, Y. Altuntaş, H. Çelebi, A. Oğuz. Çok düşük LDL düzeylerini hedefleyen lipid düşürücü tedavinin steroid hormonlar üzerine etkilerini araştıran çok merkezli, açık etiketli, ctoss-over dizaynlı, prospektif çalışma (MODEST STUDY). 11. Ulusal İç Hastalıkları Kongresi 2009, 30 Eylül-4 Ekim, Antalya. Kongre Özet Kitabı S05.
KİTAPLAR
1. Lipid Bozuklukları ve Tedavisinin Klinik Sırları. A. Tunçkale. Orhan Matbaacılık, Nisan 2008
SİTE EDİLEN YAYINLAR
Site Edilen Yayın: H. İlkova*, B. Glaser, A. Tunçkale*, N. Bağrıaçık*, E. Cerasi. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20:1353-1356.
Sitasyon Sayısı: 40
10. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion- A comprehensive review of insulin pump therapy. Archieves of Internal Medicine 2001;161(19):2293-2300.
11. Nathan DM. Insulin treatment of type 2 diabetes: The real deal. Endocrinology Rounds 2002;1:1-8.
12. Park S, Choi SB. Effects of alpha-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes. American Journal of Clinical Nutrition 2002;75(4):728-733.
13. Karvestedt L, Anderson G, Efendic S, Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. Journal of Internal Medicine 2002;251(4):307-16
14. Heise T, Sawicki PT. Does insulin preserve beta-cell function in type 2 diabetes? Journal of Internal Medicine 2002;251(4):283-285.
15. Marre M. Before oral agents fail: the case for starting insulin early. International Journal of Obesity 2002;26(Suppl 3):S25-S30.
16. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. New Engl Journal of Medicine 2002;347(17):1342-1349.
17. Campbell RK, White JR. Insulin therapy in type 2 diabetes. Journal of American Pharmacolojy Association 2002;42:602-11.
18. Udezeu E. A practical scheme for the initial out-patient management of type-2 diabetes mellitus. Tropical Doctor 2003;33(1):14-18.
19. Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism 2003;16(1):5-22.
20. Park S, Choi SB. Induction of long-term normoglycemia witout medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes-Metabolism Research and Reviews 2003;19(2):124-30.
21. Forst T, Eriksson JW, Strotman HJ, Bai S, Brunelle R, Gulliya KS, Gack S, Gudat U. Metabolic effects of mealtime insulin lispro in comparison to benclamide in early type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes 2003;11(2):97-103.
22. Kazlauskaite R, Fogelfeld L. Insulin therapy in type 2 diabetes. Disesae a Month:DM 2003;49(6):377-420.
23. Westpal SA, Palumbo PJ. Insulin and oral hypoglycemic agents should not be used in combination in the treatment of type 2 diabetes. Archieves of Internal Medicine 2003;163(15):1783-85.
24. Raskin P, Bode BW, Marks JB Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin and multipl daily injection therapy are equally effective in type 2 diabetes-A randomized, parallel-group, 24 week study. Diabetes Care 2003;26(9):2598-2603.
25. Kirk SE. Insulin pump therapy for type 2 diabetes. Current Diabetes Reports 2003;3:373-7.
26. Ryan EA, Imes S, Walace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27(5):1028-32.
27. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: Rescue, augmentation and replacement of beta-cell function. American Family Physician 2004;70(3):489-500.
28. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleveland Clinic Journal of Medicine 2004;71:385-405.
29. Del Prato S, Wishner WJ, Gromada J, Schluchter BJ. Beta cell mass plasticity in type 2 diabetes. Diabetes Obesity & Metabolism 2004;6(5):319-31
30. Murase Y, Yagi K, Sugihara M. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. Internal Medicine 2004;43(9):779-786
31. Zhou YS, Gao Y, Guo XH, Li B, Shu W, Chi JM. Effects of timely insulin treatment on protection of beta cells in a rat model of type 2 diabetes mellitus. Chinese Medical Journal 2004;17(10):1523-9.
32. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of B-cell function. Diabetes Care 2004;27:2597-2602
33. Landmark papers in insulin secretion. Cerasi E, Ferrannini E 2004:75-8
34. Sellers EAC, Dean HJ. Short-term insulin therapy in adolescents with type 2 diabetes mellitus. Journal of pediatric endocrinology & Metabolism 2004;17(11):1561-4.
35. Ferrannini E, Camastra S, Gastaldelli A, Sironi AM, Natali A, Muscelli E, Mingrone G, Mari A. Beta-cell function in obesity-effects of weight loss. Diabetes Care 2004;Suppl.3;53:S26-S33.
36. Kral JG. Preventing and treating obesity in girls and young women to curb the epidemic. Obesity Research 2004;12:1539-46.
37. Edelman SV, Morello CM. Strategies for insulin therapy in type 2 diabetes. Southern Medical Journal 2005;98(3):363-71.
38. Gernstein HC, Rosenstock J. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: Can it offer both cardiovascular protection and beta-cell preservation?Endocrinology and Metabolism Clinics of North America 2005;34(1):137-
39. Eldor R, Stern E, Milicevic Z, Raz I. Early use of insulin in type 2 diabetes. DDDiabetes Research and Clinical Practice 2005;68(1):S30-S35.
40. Deeg MA. Basic approach to managing hyperglycemia for the nonendocrinologist. American Journal of Cardiology 2005;96(4A):37E-40E.
Site Edilen Yayın: İ. Onaran, A. Özaydın, F. Akbaş, M. Gültepe, A. Tunçkale*, T. Ulutin. Are individuals with glutathione S-transferase GSTT1 null genotype more susceptible to in vitro oxidative damage. Journal of Toxicology and Environmental Health 2000;56:101-112.
Sitasyon Sayısı: 2
Site Edilen Yayın: Ö. B. Ekmekçi, O. Donma, A. Tunçkale*. Angiotensin-converting enzyme and metals in untreated essential hypertension. Biological Trace Element Research 2003;95:203-10
Sitasyon Sayısı: 2
Site Edilen Yayın: T. Karahasanoğlu, K. Memişoğlu, U. Korman, A. Tunçkale*, A. Çurgunlu*, Y. Karter*. Adult intussusception due to inverted Meckel’s Diverticulum: Laparoscopic Approach. Surgical Laparoscopy Endoscopy & Percutaneous Techniques 2003;13(1):39-41.
Sitasyon Sayısı: 1
Site Edilen Yayın: S. Köksal, A. Tunçkale*, E. Erginöz, A. Yaldıran*, F. Sipahioğlu*, E. Öztürk* & H. Erginöz. Hipertansiyon Vakalarının Epidemiyolojik Yönden Değerlendirilmesi. V. Ulusal Halk Sağlığı Kongresi 1996; Kongre Özet Kitabı 591-596.
Sitasyon Sayısı: 1
Site Edilen Yayın: Y. Karter*, S. Aran, N. Seyahi*, A. Tunçkale*, A. Yaldıran*, F. Sipahioğlu*, E. Öztürk*. The antihypertensive effects of doxazosin in arterial system; changes in peripheral vascular resistance and wall tension. European Journal of Internal Medicine 2001;5:203-7.
Sitasyon Sayısı:1
Site Edilen Yayın: , A. Tunçkale*, SN Aran, H. Karpuz, A. Dirican. Relationship between insulin resistance and end-organ damage in white coat hypertension. American Journal of Hypertension 2004;17(11):101-6.
Sitasyon Sayısı:1
Site Edilen Yayın: , Çurgunlu A, Karter Y, Tüfekçi IB, Tunçkale A, Karahasanoğlu T. Benign cystic mesothelioma: A rare cause of ascites in a case with familial Mediterranean fever. Clinical and Experimental Rheumatology 2003:21(Suppl 30);S41-S43.
Sitasyon Sayısı:1